Igc pharma expands calma trial to oklahoma, partnering with dr. david mccoy at tekton research in yukon

Potomac, md / access newswire / june 23, 2025 / igc pharma, inc. ("igc", or the "company") (nyse american:igc) today announced the addition of a new clinical trial site at tekton research in yukon, oklahoma, for its phase 2 calma study evaluating igc-ad1 for agitation in alzheimer's dementia. this expansion into the oklahoma city metropolitan area underscores igc's commitment to diversifying its trial population and addressing regional healthcare disparities.
IGC Ratings Summary
IGC Quant Ranking